focus -WSS

focus

author：comprehensive 2025-09-03 05:29:48 - browse：98

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： States should stop sabotaging methadone treatment reform

WSS

After a decade, new Gardasil ad campaign gets it (mostly) right

Abortion pill Supreme Court ruling could impact entire drug industry

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Stanford president’s abrupt resignation sparks debate

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

focus

focus

knowledge

Heart attack and stroke risk calculators need revising

Scientists boost immune system in aging mice by making it youthful

As demand for Covid shots wanes, Moderna seeks its next success

Scientists grapple with ethics of stem cell research

Dobbs anniversary: the lost opportunity of abortion as health care

States should stop sabotaging methadone treatment reform

Heart attack and stroke risk calculators need revising

Decaf coffee targeted by food safety group under obscure FDA rule

Virginia high school admissions case could be legal follow

Washington mulls new rules to avert another Change Healthcare

focus

Will generative AI in health care meet the fate of IBM's Dr. Watson?

FDA's naming rule on biosimilars has undermined competition

When a patient nears the end, a feared therapy can comfort

Readout LOUD podcast: mifepristone case, GLP

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

hotspot

explore

entertainment

hotspot